BACKGROUND: The non-polymeric paclitaxel-eluting sent Amazonia® PAX did not show differences in the occurrence of coronary restenosis or clinical events after 4 months of follow-up when compared with the Taxus® stent. However, the performance of the Amazonia® PAX stent in more complex cases and with longer angiographic follow-up has not been demonstrated. METHODS: The PAX-B study was a prospective, non-randomized, multicenter study assessing the late follow-up of patients treated with the Amazonia® PAX stent. The primary outcome was in-stent late lumen loss. RESULTS: One hundred and three patients with mean age of 61.3 ± 11.4 years were included, 26.2% were diabetics, 24.3% had acute coronary syndromes and 71.6% had type B2/C lesions. Multiple stents were performed in 4.7% of the cases and angiographic success was 100%. During hospitalization, the periprocedural acute myocardial infarction rate was 3.9% and one of these events led to target lesion revascularization (TLR). At 9-month angiographic follow-up, the median in-stent late lumen loss was 0.91 [0.50; 1.21] mm. The cumulative rates of major adverse cardiac events at the 6-month, 9-month and 12-month follow-up were 7.8%, 18.5% and 21.3%, respectively, mostly due to TLR. There was no death or stent thrombosis at 12 months. CONCLUSIONS: The stent Amazonia® PAX demonstrated excellent immediate results and high safety profile. However, angiographic recurrence rates were relatively high, due to low efficacy in inhibition of neointimal hyperplasia.
Drug-eluting stents; Paclitaxel; Coronary disease; Coronary thrombosis